|
2025
|
Invention
|
Activatable masked anti-ctla4 binding proteins.
The invention provides activatable masked anti-C... |
|
|
Invention
|
Masked il-2 cytokines and methods of use thereof.
The present invention provides, among other th... |
|
|
Invention
|
Masked il-2 cytokines and methods of use thereof. The present invention provides, among other thi... |
|
2024
|
Invention
|
Vhh masked cytokines and methods of use thereof.
The present invention relates to an VHH masked ... |
|
|
Invention
|
Vhh masked cytokines and methods of use thereof. The present invention relates to an VHH masked c... |
|
2023
|
Invention
|
Engineered cleavable carriers and methods of use thereof.
The present disclosure relates to clea... |
|
|
Invention
|
Engineered cleavable fc domain as carriers and methods of use thereof. The present disclosure rel... |
|
|
Invention
|
Targeted cytokines and methods of use thereof.
The present invention relates to targeted, masked... |
|
|
Invention
|
Engineered cd122 compositions and methods thereof. The present invention relates to an engineered... |
|
|
Invention
|
Targeted cytokines and methods of use thereof. The present invention relates to targeted, masked ... |
|
2022
|
Invention
|
Masked il-2-fc fusion polypeptides. Provided herein are cytokines or functional fragments thereof... |
|
|
Invention
|
Cleavable linkers.
The present invention discloses proteolytically cleavable peptide (CP) substr... |
|
|
Invention
|
Cleavable linkers. The present invention discloses proteolytically cleavable peptide (CP) substra... |
|
|
Invention
|
Masked interleukin-12 polypeptides. Provided herein are cytokines or functional fragments thereof... |
|
|
Invention
|
Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer.
The invention provides ... |
|
|
Invention
|
Combination of ctla4 and pd1/pdl1 antibodies for treating cancer.
The invention provides anti-CT... |
|
|
Invention
|
Combination of ctla4 and pd1/pdl1 antibodies for treating cancer. The invention provides anti-CTL... |
|
|
Invention
|
Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer. The invention provides a... |
|
|
P/S
|
Pharmaceutical products for the treatment of cancer, all of the foregoing excluding pharmaceutica... |
|
2021
|
Invention
|
Tumor-specific cleavable linkers. The present disclosure provides tumor-specific cleavable linker... |
|
|
Invention
|
Masked cytokine polypeptides. Provided herein are cytokines or functional fragments thereof that,... |
|
|
Invention
|
Masked il-15 cytokines and their cleavage products.
The present invention relates to masked IL-1... |
|
|
Invention
|
Masked il-12 cytokines and their cleavage products.
The present invention relates to masked IL-1... |
|
|
Invention
|
Masked il-2 cytokines and their cleavage products.
The present invention relates to masked IL-2 ... |
|
|
Invention
|
Masked il-15 cytokines and their cleavage products. The present invention relates to masked IL-15... |
|
|
Invention
|
Masked il-2 cytokines and their cleavage products. The present invention relates to masked IL-2 c... |
|
|
Invention
|
Masked il-12 cytokines and their cleavage products. The present invention relates to masked IL-12... |
|
2020
|
P/S
|
Pharmaceutical research and development; research and development of pharmaceuticals for the trea... |
|
2019
|
Invention
|
Activatable masked anti-ctla4 binding proteins. The invention provides activatable masked anti-CT... |
|
|
Invention
|
Anti-ctla4 antibodies and methods of use thereof.
The invention provides anti-CTLA4 binding prot... |
|
|
Invention
|
Masked cytokine polypeptides.
Provided herein are cytokines or functional fragments thereof that... |
